The comprehensive treatment of chronic hepatitis B includes liver-protective therapy, so some patients believe that the more “liver-protective” the better, which is actually wrong. First of all, the wrong medicine can harm the liver. There are many different kinds of liver-protective drugs on the market, each with its own indications, and patients are likely to choose the wrong medicine on their own. Secondly, most drugs need to be metabolized by the liver, and liver-protective drugs are no exception, so taking too many of them will increase the burden on the liver. In addition, there are drug interactions that cause adverse reactions and mask the disease. Anti-virus is the fundamental measure for the treatment of chronic hepatitis B. Anti-inflammatory and liver-protective drugs and anti-fibrotic drugs have certain auxiliary therapeutic effects, so how to use liver-protective drugs correctly? The first is to choose the correct timing of medication. In antiviral therapy, if the transaminases are significantly elevated and last for a long time, liver-protective therapy is recommended; those who fail antiviral therapy with liver function damage, such as those who develop drug resistance and relapse, liver-protective therapy is also recommended. The second is symptomatic medication. There are types of liver-protective drugs such as anti-yellowing, enzyme-lowering, detoxification, etc. Different types of liver-protective drugs have different utility, and the situation of each hepatitis patient is different, so you should follow the medical advice to use the right medicine according to your condition. Once again, the control of the type of drugs. The type of hepatoprotective drugs should not be more than three, generally do not repeat the use of similar drugs to avoid increasing the burden on the liver. There is also the control of the course of treatment. There is no fixed course of anti-inflammatory and hepatoprotective treatment, and the course of treatment should be determined according to the patient’s specific situation, especially according to the level of transaminases. For example, if antiviral therapy is effective in normalizing transaminases, it is more appropriate to take liver-protective drugs for about a month. Some hepatoprotective drugs have hormone-like effects and may rebound once they are suddenly discontinued, so the dosage should be gradually reduced to avoid stopping them too quickly. Please follow your doctor’s instructions for details. Liver-protective therapy is only an adjunct to antiviral therapy, and must be used in addition to anti-inflammatory and anti-fibrotic therapy. Patients should be reminded that most hepatitis B virus carriers do not need to use hepatoprotective drugs, as long as they have regular follow-up checkups and pay attention to a healthy diet and regular work and rest.